Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug combination increases life span of mice with ALS

01.04.2003


A new three-drug cocktail used to treat ALS, or Lou Gehrig’s Disease, may increase life span and decrease disease progression according to a study conducted at the Research Institute of the McGill University Health Centre (MUHC). The study, published in today’s issue of Annals of Neurology, is the first to look at this drug combination in a mouse model of ALS. This research was made possible by a partnership led by the Canadian Institutes of Health Research (CIHR), in conjunction with the ALS society of Canada and the Muscular Dystrophy Association of Canada (MDAC).



"Last year, we demonstrated that minocycline, a commonly prescribed antibiotic, on its own reduced disease progression, and delayed death in the ALS mice," says MUHC neuroscientist and senior author, Dr. Jean-Pierre Julien. "Findings from our current study show that a therapeutic approach based on a combination of minocycline with two other drugs is much more effective in delaying the onset of the disease and in increasing the longevity of the ALS mice."

"The results are very impressive," says Dr. Angela Genge, director of the ALS clinic at the Montreal Neurological Institute and Hospital. "The approach that Dr. Kriz and Dr Julien use is uniquely helpful in screening for potentially effective therapies in this cruel, currently incurable disease. Every gain gives us hope for the future."


"These research results give people who suffer from ALS hope, and show how well CIHR is working," said Dr. Rémi Quirion, Scientific Director of the Institute of Neurosciences, Mental Health and Addiction of the CIHR. "I have followed and admired Dr. Julien’s work for many years and it is important that the Government of Canada invest in this kind of research."

"These results provide hope to ALS patients and their families," says Centre Hospitalier de l’Universite de Montreal (CHUM) ALS clinician Dr. Monique D’Amour. "Because there is little effective treatment for ALS, new drug strategies are necessary. We will have to see if this will work in patients."

A steadily progressive and fatal neuromuscular disease, ALS erodes a person’s nervous system, eventually leading to paralysis and the inability to speak or swallow. People with ALS usually die within three to five years of diagnosis. Little is known about the cause of ALS and there is no cure. It is a disease of national importance, affecting between 1,500 and 2,000 people in Canada. Two to three Canadians a day die of ALS.

The discovery reported in this paper by Dr. Jasna Kriz, Ms. Geneviève Gowing and Dr. Julien is funded by a unique partnership between the ALS Society of Canada and the Muscular Dystrophy Association of Canada (MDAC). This partnership, in collaboration with the Canadian Institutes of Health Research (CIHR), has funded over $9 million of neuromuscular research since 2000.

"This is very exciting news for the ALS community," says Helene Vassos, interim National Executive Director for the ALS Society of Canada. "We are pleased that research, funded by our collaborative initiative with the MDAC and CIHR continues to result in important discoveries."

Dr. Julien, who is also a professor of Neurosciences at McGill University says that Dr. Kriz looked at the effect of combining three different drugs on the disease progression of ALS mice. The three drugs administered include minocyline- an antibiotic with anti-inflammatory properties, riluzole – the traditional ALS drug, and nimodipine – a drug that blocks calcium channels and normally used to treat brain hemorrhage and for prevention of migraine headache. Dr. Kriz compared the life span, muscle strength, nerve cell loss, and inflammatory response in ALS-mice who were fed a regular diet with those given food containing the three-drug cocktail. The mice fed the drug cocktail lived substantially longer, had a delayed onset of neuronal and muscle deterioration. "Our findings demonstrate the merit of a drug combination approach for treatment of a disease with complex degeneration pathways. The three drugs are currently available and we hope that our study will justify a trial on ALS patients," says Dr. Julien.

Christine Zeindler | EurekAlert!
Further information:
http://www.mcgill.ca/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>